Whole genome sequencing refines stratification and therapy of patients with clear cell renal cell carcinoma
-
Published:2024-07-15
Issue:1
Volume:15
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Culliford RichardORCID, Lawrence Samuel E. D., Mills CharlieORCID, Tippu Zayd, Chubb Daniel, Cornish Alex J.ORCID, Browning Lisa, Kinnersley BenORCID, Bentham Robert, Sud AmitORCID, Pallikonda HusaynORCID, Afshar Mehran, Akala Oyeyemi, Brown Janet, Faust Guy, Fife Kate, Foy Victoria, Germanou Styliani, Giles Megan, Grieco Charlotte, Grummet Simon, Jain Ankit, Kanwar Anuradha, Protheroe Andrew, Raza Iwan, Rehan Ahmed, Rudman Sarah, Santiapillai Joseph, Sarwar Naveed, Seeva Pavetha, Strong Amy, Toki Maria, Tran Maxine, Tutika Rippie, Waddell Tom, Wheater Matthew, Frangou AnnaORCID, Gruber Andreas J.ORCID, Litchfield KevinORCID, Wedge DavidORCID, Larkin James, Turajlic SamraORCID, Houlston Richard S.ORCID,
Abstract
AbstractClear cell renal cell carcinoma (ccRCC) is the most common form of kidney cancer, but a comprehensive description of its genomic landscape is lacking. We report the whole genome sequencing of 778 ccRCC patients enrolled in the 100,000 Genomes Project, providing for a detailed description of the somatic mutational landscape of ccRCC. We identify candidate driver genes, which as well as emphasising the major role of epigenetic regulation in ccRCC highlight additional biological pathways extending opportunities for therapeutic interventions. Genomic characterisation identified patients with divergent clinical outcome; higher number of structural copy number alterations associated with poorer prognosis, whereas VHL mutations were independently associated with a better prognosis. The observations that higher T-cell infiltration is associated with better overall survival and that genetically predicted immune evasion is not common supports the rationale for immunotherapy. These findings should inform personalised surveillance and treatment strategies for ccRCC patients.
Publisher
Springer Science and Business Media LLC
Reference99 articles.
1. Bukavina, L. et al. Epidemiology of renal cell carcinoma: 2022 update. Eur. Urol. 82, 529–542 (2022). 2. Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenario. Cancer Treat. Rev. 115, 102528 (2023). 3. Choueiri, T. K. et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N. Engl. J. Med. 385, 683–694 (2021). 4. Pal, S. K. et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet 400, 1103–1116 (2022). 5. Motzer, R. J. et al. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. Lancet 401, 821–832 (2023).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|